AAM Stares Into The Biosimilar Void

Report Offers ‘Sobering Wake-Up Call’ For Stakeholders

12 Feb 2025

Discussing a new report highlighting the lack of US biosimilar competition on the cards for the majority of biologics losing exclusivity in the next ten years, the AAM’s Access! 2025 conference heard that the “sobering” findings should act as a “wake-up call for stakeholders.”

The US ‘Biosimilar Void’ means that only 12 of 118 biologics losing exclusivity over the next ten years have biosimilars in the pipeline (Shutterstock)

As the US approaches the tenth anniversary of its first biosimilar approval and launch, things could be going better for the market. That was the overall impression provided at the Association for Accessible Medicines’ Access! 2025 meeting in Amelia Island, Florida, at the start of February, especially during a session that highlighted the lack of biosimilar competition for most of the biologics that are facing an upcoming loss of exclusivity over the next decade.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

After A Decade Of US Biosimilars, ‘The Challenges Are Becoming More Clear’

12 Mar 2025

• By Dave Wallace

As the US marks 10 years since the first biosimilar approval and launch, AAM Biosimilars Council executive director Craig Burton talks to Generics Bulletin about the lessons learned so far and the path ahead, including how to move on from market models that have proved to be “not appropriate” for biosimilars.

‘You’re Going To See A Much More Aggressive Approach’ – AAM Chief Murphy Sets Out Plans To Engage On Tariffs, Shortages And The IRA

05 Mar 2025

• By Dave Wallace

In a wide-ranging conversation, the AAM’s president and CEO John Murphy talks to Generics Bulletin about how the US industry association is planning to gain traction with the new Trump administration by adopting “a much more aggressive communications approach” on topics including medicines shortages, trade tariffs, PBM reform, the IRA and biosimilar interchangeability.

‘I’m Focused On The Opportunities Rather Than The Challenges’ – AAM Chair Haruvi Examines The New US Landscape

26 Feb 2025

• By Dave Wallace

A new US presidential administration brings both challenges and opportunities for the off-patent industry. Speaking to Generics Bulletin on the sidelines of the AAM’s annual conference earlier this month, the association’s chair and Sandoz North America president Keren Haruvi discusses how the group plans to make its voice heard on key priorities including tariffs, PBM reform, and regulatory streamlining.